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Background and Objectives: A dynamic prediction model for patients with soft
tissue sarcoma of the extremities was previously developed to predict updated
overall survival probabilities throughout patient follow‐up. This study updates and
externally validates the dynamic model.
Methods: Data from 3826 patients with high‐grade extremity soft tissue sarcoma,
treated surgically with curative intent were used to update the dynamic PERsona-
lised SARcoma Care (PERSARC) model. Patients were added to the model devel-
opment cohort and grade was included in the model. External validation was
performed with data from 1111 patients treated at a single tertiary center.
Results: Calibration plots show good model calibration. Dynamic C‐indices suggest
that the model can discriminate between high‐ and low‐risk patients. The dynamic
C‐indices at 0, 1, 2, 3, 4, and 5 years after surgery were equal to 0.697, 0.790, 0.822,
0.818, 0.812, and 0.827, respectively.
Conclusion: Results from the external validation show that the dynamic PERSARC
model is reliable in predicting the probability of surviving an additional 5 years from
a specific prediction time point during follow‐up. The model combines patient‐,
treatment‐specific and time‐dependent variables such as local recurrence and dis-
tant metastasis to provide accurate survival predictions throughout follow‐up and is
available through the PERSARC app.
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1 | INTRODUCTION
Extremity soft tissue sarcomas (eSTS) not only represent a wide
variety of histological subtypes, sizes, and grades but also affect
patients of all age groups. This reflects the clear and substantial
differences in their clinical course and prognosis.1 As treatment
protocols differ for specific patients between institutes and coun-
tries, several prognostic prediction models for overall survival (OS)
and local recurrence (LR) have been developed.2–8 However, these
models are designed to estimate prognosis at the time of treatment
or diagnosis and do not take new events that occur during treatment
and follow‐up into account. In addition, they do not account for
possible time‐varying effects of baseline risk factors.
A dynamic prediction model for patients with eSTS was
therefore developed, the dynamic PERsonalised SARcoma Care
(PERSARC) model, to predict the probability of surviving an addi-
tional 5 years from a prediction time point during follow‐up.9 Be-
fore the introduction of the dynamic PERSARC model, prediction
models for eSTS patients were limited to predictions from baseline,
for example, time of surgery or diagnosis.2–8 The dynamic PESARC
model uses updated patient information such as the occurrence of
LR and distant metastasis (DM) which become available during
follow‐up, to update predictions over time. Additionally, it accounts
for the time‐varying effects of histology subtype and surgical
margin on survival. The dynamic model has been internally vali-
dated through the use of cross‐validation, but so far, no external
validation has been performed. As the original publication on dy-
namic PERSARC did not account for the grade, the model is up-
dated to meet current clinical demands and improve possibilities for
implementation.
The aim of this study was to update and improve the existing
dynamic prediction model as well as to validate it using a large ex-
ternal data set. The model was adapted in two ways: (1) new patients
were added to the model development cohort, and (2) the grade of
disease was included in the model.
2 | MATERIALS AND METHODS
2.1 | Study design
In this study, the original dynamic prediction model developed by
Rueten‐Budde et al.9 was updated and externally validated, using
a retrospectively collected cohort of patients with eSTS.
The model development data were augmented for the update and
contained data from Leiden University Medical Center, Royal
Orthopaedic Hospital, Netherlands Cancer Institute, Mount Sinai
Hospital, the Norwegian Radium Hospital, Aarhus University
Hospital, Ska ̊ne University Hospital, Medical University
Graz, Royal Marsden Hospital, Erasmus MC Cancer Institute,
Radboud University Medical Center, University Medical Center
TABLE 1 Patient demographics for the two cohorts used to
develop and to validate the model
Characteristics Development External
Total 3826 1111
Age, mean (SD) 59.40 (18.10) 55.46 (17.03)
Gender (%)
Female 1680 (43.9) 504 (45.4)
Male 2011 (52.6) 607 (54.6)
Unknown 135 (3.5) 0 (0.0)
Tumor size in cm, mean (SD) 9.04 (5.77) 8.33 (5.66)
Margin (%)
R1–2 515 (13.5) 142 (12.8)
R0 3028 (79.1) 969 (87.2)
Unknown 283 (7.4) 0 (0.0)
Histology (%)
Myxofibrosarcoma 689 (18.0) 197 (17.7)
MPNST 261 (6.8) 60 (5.4)
Synovial sarcoma 411 (10.7) 122 (11.0)
MFH/UPS and NOS 1204 (31.5) 202 (18.2)
Spindle cell 191 (5.0) 0 (0.0)
LMS 368 (9.6) 150 (13.5)
LPS 388 (10.1) 167 (15.0)
Other 314 (8.2) 213 (19.2)
Tumor depth (%)
Deep 2493 (65.2) 802 (72.2)
Superficial 912 (23.8) 309 (27.8)
Unknown 421 (11.0) 0 (0.0)
Grade
2 639 (16.7) 432 (38.9)
3 3111 (81.3) 679 (61.1)
Unknown 76 (2.0) 0 (0.0)
Radiotherapy (%)
No radiotherapy 1331 (34.8) 474 (42.7)
Neoadjuvant 517 (13.5) 138 (12.4)
Adjuvant 1878 (49.1) 499 (44.9)
Unknown 100 (2.6) 0 (0.0)
Chemotherapy (%)
No 3189 (83.4) 739 (66.5)
Yes 470 (12.3) 372 (33.5)
Unknown 167 (4.4) 0 (0.0)
Note: Histology “Other”, angiosarcoma, malignant rhabdoid tumor,
alveolar soft part sarcoma, epithelioid sarcoma, clear cell sarcoma,
embryonal rhabdomyosarcoma, rhabdomyosarcoma (adult form), giant
cell sarcoma, malignant granular cell tumor, conventional fibrosarcoma,
unclassified soft tissue sarcoma, and undifferentiated sarcoma; Tumor
depth: relative to the investing fascia.
Abbreviations: cm, centimeters; LMS, leiomyosarcoma; LPS, liposarcoma;
MFH/UPS, malignant fibrous histiocytoma/undifferentiated pleomorphic
sarcoma; MPNST, malignant peripheral nerve sheath tumor; sarcoma –
NOS, (pleomorphic) soft tissue sarcomas not‐otherwise‐specified;
SD, standard deviation.
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Groningen, Haukeland University Hospital, Helios Klinikum
Berlin‐Buch, MedUni Vienna, Vienna General Hospital, and the
EORTC trial 62931, a randomized controlled trial which studied
the effect of intensive adjuvant chemotherapy on several out-
come measures.
External data were provided by Istituto Nazionale dei Tumori. For
both, the model development and external cohort data were collected
from centers between January 1, 2000, and December 31, 2014. Data
from the EORTC trial 62931, which is part of the development cohort,
were collected between February 1995, and December 2003.
The outcome of interest was OS, defined as the time from sur-
gery to death due to any cause or last recorded follow‐up. The dy-
namic model predicts 5‐year dynamic overall survival (DOS) from a
particular prediction time point during follow‐up. For example, at
1‐year postsurgery, the model predicts the probability of surviving
an additional 5 years (therefore until 6‐year postsurgery). To de-
termine the predictive performance of the model, calibration and
discrimination were evaluated with the external data set. Ethical
approval for this study was waived by the Institutional Review Board
CME (G16.022), because clinical data were collected from medical
records and were pseudo‐anonymized.
2.2 | Patients and variables
Selection and exclusion criteria were identical for the model develop-
ment cohort and the external cohort.9 All patients were selected from
the sarcoma registry based on histological diagnosis from each hospital.
Histologically, tumors were classified according to the WHO's criteria1
and patients were grouped into eight categories. Included eSTS subtypes
included high‐grade (FNCLCC Grades II and III10) angiosarcoma, malig-
nant peripheral nerve sheath tumor, synovial sarcoma, spindle cell
sarcoma, myxofibrosarcoma, liposarcoma, leiomyosarcoma, malignant
fibrous histiocytoma/undifferentiated pleomorphic sarcoma, (pleo-
morphic) soft tissue sarcomas not‐otherwise‐specified, epithelioid sar-
coma, clear cell sarcoma, rhabdomyosarcoma (adult form), conventional
fibrosarcoma, giant cell sarcoma, malignant granular cell tumor,
unclassified soft tissue sarcoma, and undifferentiated sarcoma.
Patients were excluded if they were initially treated without curative
intent, presented with LR or DM, had Kaposi's or rhabdomyosarcoma
F IGURE 1 Kaplan–Meier curves for development and external
cohort [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 2 Number of patients at risk in development and external data set, respectively. Red: patients with local recurrence (LR) and distant
metastasis (DM); pink: patients with DM; green: patients with LR; blue: patients without LR or DM [Color figure can be viewed at
wileyonlinelibrary.com]
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(pediatric form), had tumor in their abdomen, thorax, head, or neck, or
received isolated limp perfusion as (neo‐) adjuvant treatment.
Three types of risk factors were included in the dynamic model.
Patient‐specific predictors assessed at baseline: age (years), tumor size
by the largest diameter measured at pathological examination (cm),
tumor depth in relation to investing fascia (deep/superficial), grade
(II/III), and histological subtype according to the WHO classification.1
Treatment‐related predictors measured at baseline: radiotherapy
((neo)adjuvant/no radiotherapy), surgical margin categorized accord-
ing to the categorical R‐system, “R0” for negative margin and “R1–2”
for a positive margin with tumor cells in the inked surface of the
resection margin.11 Risk factors measured during follow‐up: LR de-
fined as the presence of pathological and/or radiologically confirmed
tumor at the site where it was originally detected, more than 2 months
after primary surgery and DM defined as radiological evidence of
systemic spread of tumor distant from the primary tumor site.
The original dynamic prediction model was based on 2232
patients.9 For the revised model, additional data were collected re-
sulting in 3826 patients for the development of the updated dynamic
model. For external validation, 1111 patients were considered.
2.3 | Statistical analysis
The dynamic prediction model developed in Rueten‐Budde et al.9
was revised by adding more patients and the variable grade to the
model. The prediction model was based on landmark methodology.
Technical details about landmark models for dynamic prediction are
provided in van Houwelingen and Putter.12 Additionally, the asso-
ciation between chemotherapy and survival was investigated.
The predictive ability of the updated model was assessed in
terms of calibration and discrimination using an external data set.
TABLE 2 Dynamic prediction model for overall survival: hazard
ratio (HR) along with 95% confidence interval (n = 3826)
HR 95% CI p
Covariates with time‐constant effects
Age (ref: 60 years, per 10 years)
Age 1.366 1.304–1.431 <.001
Age2 1.052 1.028–1.076 <.001
Tumor size (ref: 0 cm, per 1 cm)
Size 1.158 1.116–1.202 <.001
Size2 0.996 0.995–0.998 <.001
Tumor depth (superficial vs. deep) 0.790 0.673–0.927 .004
Grade (3 vs. 2) 1.425 1.174–1.730 <.001
Radiotherapy (RT)
No RT 1
Neoadjuvant 0.719 0.583–0.886 .002
Adjuvant 0.818 0.716–0.936 .003
Local recurrence (yes vs. no) 2.232 1.892–2.634 <.001
Distant metastasis (yes vs. no) 6.446 5.662–7.338 <.001
Covariates with time‐varying effects
Prediction time (ref: time of surgery,
per year)
tp 0.507 0.415–0.621 <.001
tp




MPNST 2.132 1.633–2.783 <.001
Synovial sarcoma 1.458 1.145–1.856 .002
MFH/UPS and NOS 1.207 1.004–1.452 .045
Spindle cell 1.396 1.054–1.848 .020
LMS 1.065 0.819–1.386 .638
LPS 0.915 0.706–1.185 .501
Other 1.419 1.095–1.841 .008
Linear time‐varying effect
Myxofibrosarcoma 1
MPNST 0.845 0.669–1.068 .159
Synovial sarcoma 1.261 1.037–1.534 .020
MFH/UPS and NOS 1.002 0.851–1.179 .981
Spindle cell 1.058 0.824–1.357 .660
LMS 1.166 0.941–1.444 .160
LPS 1.010 0.812–1.256 .929
Other 0.863 0.663–1.124 .276
Quadratic time‐varying effect
Myxofibrosarcoma 1
MPNST 1.000 0.947–1.056 1.000
Synovial sarcoma 0.939 0.897–0.983 .007
MFH/UPS and NOS 1.009 0.976–1.044 .585
Spindle cell 0.972 0.906–1.043 .434
LMS 0.989 0.946–1.034 .636
LPS 1.011 0.967–1.058 .622
Other 1.019 0.963–1.078 .510
(Continues)
TABLE 2 (Continued)
HR 95% CI p
Margin
Constant
R0 versus R1–2 0.827 0.698–0.981 .029
Linear time‐varying effect
R0 versus R1–2 1.334 1.114–1.597 .002
Quadratic time‐varying effect
R0 versus R1–2 0.954 0.918–0.990 .014
Note: Histology “Other”, angiosarcoma, malignant rhabdoid tumor,
alveolar soft part sarcoma, epithelioid sarcoma, clear cell sarcoma,
embryonal rhabdomyosarcoma, rhabdomyosarcoma (adult form), giant
cell sarcoma, malignant granular cell tumor, conventional fibrosarcoma,
unclassified soft tissue sarcoma, and undifferentiated sarcoma; Tumor
depth: relative to the investing fascia.
Abbreviations: CI, confidence interval; HR, hazard ratio; LMS,
leiomyosarcoma; LPS, liposarcoma; MFH/UPS, malignant fibrous
histiocytoma/undifferentiated pleomorphic sarcoma; MPNST, malignant
peripheral nerve sheet tumor; sarcoma – NOS, (pleomorphic) soft tissue
sarcomas not‐otherwise‐specified; tp, prediction time points.
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Model discrimination refers to how well the model is able to dis-
criminate between high‐ and low‐risk patients; dynamic C‐indices12
were computed to evaluate the performance of the model. A C‐index
equal to one corresponds to perfect discrimination and a C‐index of
0.5 means that the model predicts just as well as flipping a coin.13
Model calibration on the external data refers to how well predicted
and observed survival probabilities have similar values and was as-
sessed with yearly calibration plots.
Calibration plots visualize calibration at a particular prediction
time point (e.g., 1‐year postsurgery). Patients at risk at a specific time
were divided into eight prognostic groups based on their predicted




F IGURE 3 Calibration plots for predictions of 5‐year DOS from 0‐, 1‐, 2‐, 3‐, 4‐, and 5‐year postsurgery. DOS, dynamic overall survival [Color
figure can be viewed at wileyonlinelibrary.com]
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5‐year DOS for patients in the external data set and based on these
probabilities risk groups were made. Five years after the prediction
time point (e.g., 6‐year postsurgery), the observed survival prob-
abilities of the risk groups were estimated by applying Kaplan–Meier's
method. In the calibration, each point represents a risk group. If the
points lay on the diagonal (x = y), predicted and observed survival
are the same, implying that the predictions for the risk groups were
perfect. The arbitrary choice for the number of risk groups was made
based on the number of patients at risk over time; initially,
1111 patients were at risk, however, 5 years after surgery only 529
patients remain in the risk set. To have a reasonable number of
patients per risk group even at 5‐year postsurgery, eight risk groups
were chosen.
The items on the checklist of the Transparent Reporting of a
multivariable prediction model for Individual Prognosis Or Diagnosis
(TRIPOD) were considered during model development.14 Statistical
analyses were performed in the R‐software environment.15 All
p values were derived from a two‐sided test and p < .05 was
considered significant.
3 | RESULTS
The model was developed on a cohort of 3826 patients with median
follow‐up equal to 6.00 years (95% confidence interval
[CI] = 5.86–6.18), assessed with the reverse Kaplan–Meier method.16
The external validation cohort consisted of 1111 patients with a
median follow‐up equal to 6.89 years (95% CI = 6.47–7.61). Table 1
provides a summary of the patient characteristics for the cohort used
to develop the dynamic model and the external cohort.
Figure 1 shows Kaplan–Meier survival curves for both devel-
opment and external cohort.
An overview of the number of patients at risk in the develop-
ment and external data set is given in Figure 2 together with in-
formation about the disease status. In the development cohort, in
total 1602 patients died, 241 patients developed LR, 949 DM, and
385 developed both. In the external cohort, 306 patients died, 70
had LR, 279 DM, and 77 developed both.
Table 2 shows hazard ratios (HRs) together with 95% CI for the
risk factors included in the revised dynamic model. Age and tumor
size are both modeled by a linear and a quadratic term (age in steps
of 10 years and size in steps of 1 cm). This means that the HRs
consist of two components: the linear (HRlin) and the quadratic effect
(HRquad). For example, for the risk factor age, the HR of an 80‐year‐
old compared to a 60‐year‐old patient (reference) is equal to




where “step” corresponds to the age difference between the two
patients in units of 10 years.
Surgical margin and histology subtype are modeled as time‐
varying variables, which means that the effect on the outcome
changes over time. For example, the HR 1‐year postoperative for a
patient with R0 margin compared to an R1–2 margin is equal to
= × −
× − = ×
× =
HR constant lineartime varyingeffect
quadratictime varyingeffect
[ ( )







where tp = 1 and tp
2 = 1. The HR changes from 0.827 at the time of
surgery to 1.052 a year later. The model shows that the effect of
surgical margin changes from being protective at surgery time to
having no effect on survival after 1 year.
In a preliminary analysis, the association of risk factors to the
outcome of chemotherapy treatment (yes (neoadjuvant or adjuvant)
vs. no) was evaluated. Most baseline risk factors showed a significant
association (age, tumor size, depth, histology, radiotherapy, and
grade). Country of treatment was significantly associated with che-
motherapy treatment. This means that, correcting for the other risk
factors (age, tumor size, depth, margin, histology, radiotherapy, and
grade) in the model, countries had different approaches in giving
chemotherapy treatment. The association of chemotherapy to sur-
vival was investigated by including this risk factor in the dynamic
model and no significant effect was found (chemotherapy yes vs. no;
HR = 1.131; 95% CI = 0.946–1.352; p = .178). Chemotherapy was
therefore not included in the updated dynamic prediction model.
The quality of the model can be assessed from the calibration
plots (Figure 3A–F). Each point in the plot represents a
risk group; the figure shows they are relatively close to the diagonal
line implying that predictions are accurate. Figure 3 also suggests
that the model generally slightly underestimated survival.
The discriminative ability of the model was assessed with dy-
namic C‐indices, with values equal to 0.697, 0.790, 0.822, 0.818,
0.812, and 0.827 at 0, 1, 2, 3, 4, and 5 years after surgery respec-
tively. High values for the C‐indices are due to the strong predictive
value of DM on survival. A patient who experiences DM has a worse
prognosis compared to a patient without DM.
4 | DISCUSSION AND CONCLUSIONS
The previously developed dynamic prediction model has been up-
dated and successfully externally validated. The sample size of the
model development cohort was increased from 2232 to 3826 pa-
tients and the risk factor grade was added to the updated model.9
The model can estimate the probability of surviving an additional
5 years from a prediction time point during follow‐up. It can be used
from the time of surgery up until 5‐year postsurgery for patients
with high‐grade eSTS treated with curative intent.
Even though calibration plots showed that predicted survival
was close to observed survival the model generally under-
estimated survival in the external cohort. Kaplan–Meier curves
estimated for the development and external cohort indicate that
the external cohort had better survival. There are several pos-
sible reasons for the underestimation of survival: the effect of
risk factors might be different in the development cohort com-
pared to the external cohort, or patients might differ in terms of
an unobserved covariate which might affect survival and cannot
be taken into account.
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The association of chemotherapy with survival is controversial,
and its indication greatly depends on other risk factors. When added
to the dynamic model, chemotherapy showed no significant associa-
tion with survival.
The updated dynamic prediction models is implemented in the
updated PERSARC application; available for free at the Apple Store
and Google Play Store.
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